Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

450 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Pao W, et al. PLoS Med. 2005 Mar;2(3):e73. doi: 10.1371/journal.pmed.0020073. Epub 2005 Feb 22. PLoS Med. 2005. PMID: 15737014 Free PMC article.
Induction chemotherapy for non-small cell lung cancer with clinically evident mediastinal node metastases: the role of postoperative radiotherapy.
Armstrong JG, Martini N, Kris MG, Harrison LB. Armstrong JG, et al. Int J Radiat Oncol Biol Phys. 1992;23(3):605-13. doi: 10.1016/0360-3016(92)90018-d. Int J Radiat Oncol Biol Phys. 1992. PMID: 1319427 Clinical Trial.
A reappraisal of the role of prophylactic cranial irradiation in limited small cell lung cancer.
Rosenstein M, Armstrong J, Kris M, Shank B, Scher H, Fass D, Harrison L, Fuks Z, Leibel S. Rosenstein M, et al. Int J Radiat Oncol Biol Phys. 1992;24(1):43-8. doi: 10.1016/0360-3016(92)91019-j. Int J Radiat Oncol Biol Phys. 1992. PMID: 1324901 Clinical Trial.
Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer.
Rusch VW, Reuter VE, Kris MG, Kurie J, Miller WH Jr, Nanus DM, Albino AP, Dmitrovsky E. Rusch VW, et al. J Thorac Cardiovasc Surg. 1992 Nov;104(5):1465-9. J Thorac Cardiovasc Surg. 1992. PMID: 1331621
Phase II trial of esorubicin (4'deoxydoxorubicin, DxDx) in patients with small cell lung cancer.
Rigas JR, Kris MG, Gralla RJ, Heelan RT, Marks LD. Rigas JR, et al. Invest New Drugs. 1991 May;9(2):187-90. doi: 10.1007/BF00175087. Invest New Drugs. 1991. PMID: 1651908 Clinical Trial.
Eleven patients with small cell lung cancer who had previously received chemotherapy were given esorubicin (25 mg/m2 intravenously) every 3 weeks. ...
Eleven patients with small cell lung cancer who had previously received chemotherapy were given esorubicin (25 mg/m2 intravenously) e …
Twice daily thoracic irradiation for limited small cell lung cancer.
Armstrong JG, Rosenstein MM, Kris MG, Shank BM, Scher HI, Fass DE, Harrison LB, Leibel SA, Fuks ZY. Armstrong JG, et al. Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1269-74. doi: 10.1016/0360-3016(91)90285-c. Int J Radiat Oncol Biol Phys. 1991. PMID: 1657842 Clinical Trial.
Limited small cell lung cancer: prognostic significance of a complete response to the induction phase of chemotherapy followed by thoracic irradiation.
Armstrong JG, Rosenstein MM, Scher HI, Fass DE, Zelefsky MJ, Kris MG. Armstrong JG, et al. Radiology. 1991 Mar;178(3):875-8. doi: 10.1148/radiology.178.3.1847240. Radiology. 1991. PMID: 1847240 Clinical Trial.
Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer.
Berger MZ, Kris MG, Gralla RJ, Marks LD, Potanovich LM, Dimaggio JJ, Heelan RT. Berger MZ, et al. Am J Clin Oncol. 1991 Apr;14(2):124-6. doi: 10.1097/00000421-199104000-00006. Am J Clin Oncol. 1991. PMID: 1851387
Sixteen patients with stage III or IV non-small-cell lung cancer who had not previously received chemotherapy were given amonafide at an initial dose of 300 mg/m2 i.v. daily for 5 days every 21 days. ...
Sixteen patients with stage III or IV non-small-cell lung cancer who had not previously received chemotherapy were given amonafide at an ini …
450 results
Jump to page
Feedback